We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.97B
AUM Growth
-$356M
Cap. Flow
+$116M
Cap. Flow %
2.92%
Top 10 Hldgs %
30.63%
Holding
140
New
5
Increased
76
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$22.5M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$21.2M
3
DXCM icon
DexCom
DXCM
+$20.7M
4
IDXX icon
Idexx Laboratories
IDXX
+$20.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.3M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$18.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$18M
3
IMRX icon
Immuneering
IMRX
+$17.6M
4
WHWK
Whitehawk Therapeutics
WHWK
+$13M
5
VERV
Verve Therapeutics
VERV
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.08%
2 Consumer Staples 1.53%
3 Industrials 0.67%
4 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
Alnylam Pharmaceuticals
ALNY
$29B
$54.3M 1.37%
332,500
– –
DXCM icon
27
DexCom
DXCM
$33.1B
$53.2M 1.34%
416,000
+189,000
+83% +$20.7M
ZLAB icon
28
Zai Lab
ZLAB
$2.65B
$53M 1.34%
1,205,900
+25,200
+2% +$1.22M
NVRO
29
DELISTED
NEVRO CORP.
NVRO
$52.2M 1.31%
721,500
+7,500
+1% +$541K
ACHC icon
30
Acadia Healthcare
ACHC
$2.96B
$49.4M 1.24%
753,500
+5,000
+0.7% +$290K
ASND icon
31
Ascendis Pharma A/S
ASND
$16.8B
$49M 1.23%
417,500
+17,500
+4% +$2.03M
MRTX
32
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$46M 1.16%
559,734
+149,319
+36% +$15.3M
PEN icon
33
Penumbra
PEN
$12.8B
$45.4M 1.14%
204,500
+56,000
+38% +$12.4M
EXAS
34
DELISTED
Exact Sciences
EXAS
$39.9M 1%
570,000
– –
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
$39M 0.98%
270,500
+14,500
+6% +$1.96M
SRRA
36
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$37.7M 0.95%
1,174,786
-10,007
-0.8% -$287K
MIRM icon
37
Mirum Pharmaceuticals
MIRM
$6.02B
$36.7M 0.92%
1,666,208
+127,394
+8% +$2.6M
EHC icon
38
Encompass Health
EHC
$12.5B
$35.7M 0.9%
631,643
– –
WRBY icon
39
Warby Parker
WRBY
$3.26B
$35.1M 0.88%
1,038,500
+314,500
+43% +$10.2M
SRPT icon
40
Sarepta Therapeutics
SRPT
$1.81B
$33.4M 0.84%
428,000
+4,000
+0.9% +$306K
NVAX icon
41
Novavax
NVAX
$1.3B
$33M 0.83%
448,200
+23,200
+5% +$2.07M
KYMR icon
42
Kymera Therapeutics
KYMR
$9.03B
$32M 0.81%
755,875
+13,810
+2% +$583K
ARVN icon
43
Arvinas
ARVN
$588M
$30.8M 0.78%
457,600
+400
+0.1% +$27.3K
CNMD icon
44
CONMED
CNMD
$1.48B
$30.1M 0.76%
202,500
– –
WST icon
45
West Pharmaceutical
WST
$24.8B
$28.4M 0.72%
69,250
+23,750
+52% +$9.3M
CVET
46
DELISTED
Covetrus, Inc. Common Stock
CVET
$28.1M 0.71%
1,675,000
+13,300
+0.8% +$233K
MDGL icon
47
Madrigal Pharmaceuticals
MDGL
$11.9B
$26.8M 0.68%
273,500
+4,100
+2% +$346K
NVTA
48
DELISTED
Invitae Corporation
NVTA
$26.5M 0.67%
3,323,821
+523,578
+19% +$5.27M
ACCD
49
DELISTED
Accolade Inc
ACCD
$26.4M 0.67%
1,505,000
+308,000
+26% +$5.67M
ABCM
50
DELISTED
Abcam PLC
ABCM
$26.2M 0.66%
1,432,900
+180,400
+14% +$3.19M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Rock Springs Capital Management held 140 positions worth $3.97B, down 8.2% from $4.33B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rock Springs Capital Management's Q1 2022 filing shows 5 new, 76 increased, 8 reduced and 5 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M. The largest sale was HCA Healthcare, an estimated $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2022 buy was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M.
  • Rock Springs Capital Management added most to DexCom in Q1 2022, an estimated $20.7M increase.
  • Rock Springs Capital Management's biggest Q1 2022 reduction was HCA Healthcare, cutting an estimated $18.8M.
  • Rock Springs Capital Management fully exited Immuneering in Q1 2022, selling an estimated $17.6M.
  • Rock Springs Capital Management's ten largest holdings make up 31% of its $3.97B portfolio in Q1 2022.
  • Rock Springs Capital Management opened 5 new positions and closed 5 in Q1 2022.
  • Rock Springs Capital Management's portfolio value fell 8.2% quarter-over-quarter to $3.97B.

Based on Rock Springs Capital Management's 13F filing for Q1 2022, filed 16 May 2022.